We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+14.25%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$966M
AUM Growth
+$269M
(+39%)
Cap. Flow
+$319M
Cap. Flow
% of AUM
33.08%
Top 10 Holdings %
Top 10 Hldgs %
49.6%
Holding
104
New
32
Increased
25
Reduced
14
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Smith & Nephew
SNN
|
+$27.6M |
| 2 |
Rigel Pharmaceuticals
RIGL
|
+$20.3M |
| 3 |
SI-BONE Inc
SIBN
|
+$18.8M |
| 4 |
Natera
NTRA
|
+$14.1M |
| 5 |
Jasper Therapeutics
JSPR
|
+$13.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVRx
CVRX
|
+$18.6M |
| 2 |
Vericel Corp
VCEL
|
+$16.9M |
| 3 |
Eli Lilly
LLY
|
+$14.3M |
| 4 |
HCA Healthcare
HCA
|
+$8.29M |
| 5 |
Krystal Biotech
KRYS
|
+$8.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.2% |
| 2 | Consumer Staples | 1.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
YMAB
76
DELISTED
Y-mAbs Therapeutics
YMAB
| $437K | 0.05% |
87,182
| – | – |
|
77
MDxHealth
MDXH
$23.7M
| $194K | 0.02% |
+60,000
| New | +$274K |
|
78
AnaptysBio
ANAB
$1.68B
| – | – |
-14,727
| Closed | -$456K |
|
|
JBIO
79
Jade Biosciences
JBIO
$1.34B
| – | – |
-6,203
| Closed | -$6.36M |
|
80
CRISPR Therapeutics
CRSP
$5.17B
| – | – |
-22,000
| Closed | -$894K |
|
|
81
CVRx
CVRX
$63.4M
| – | – |
-1,014,640
| Closed | -$18.6M |
|
82
DexCom
DXCM
$32B
| – | – |
-40,000
| Closed | -$4.53M |
|
83
Enovis
ENOV
$1.53B
| – | – |
-95,000
| Closed | -$5.08M |
|
84
Establishment Labs
ESTA
$2.28B
| – | – |
-39,920
| Closed | -$2.62M |
|
|
85
HCA Healthcare
HCA
$89.5B
| – | – |
-34,550
| Closed | -$8.29M |
|
86
Illumina
ILMN
$28.4B
| – | – |
-24,941
| Closed | -$4.91M |
|
87
Intuitive Surgical
ISRG
$134B
| – | – |
-9,600
| Closed | -$2.55M |
|
88
OrthoPediatrics
KIDS
$595M
| – | – |
-7,471
| Closed | -$297K |
|
|
89
Eli Lilly
LLY
$1.06T
| – | – |
-39,100
| Closed | -$14.3M |
|
90
Neogen
NEOG
$2.5B
| – | – |
-143,500
| Closed | -$2.19M |
|
91
Orthofix Medical
OFIX
$419M
| – | – |
-295,300
| Closed | -$6.06M |
|
92
Penumbra
PEN
$12.8B
| – | – |
-9,300
| Closed | -$2.07M |
|
93
PepGen
PEPG
$197M
| – | – |
-10,000
| Closed | -$134K |
|
94
Protagonist Therapeutics
PTGX
$9.44B
| – | – |
-236,000
| Closed | -$2.57M |
|
|
RNAM
95
DELISTED
Avidity Biosciences
RNAM
| – | – |
-310,000
| Closed | -$6.88M |
|
96
STAAR Surgical
STAA
$1.21B
| – | – |
-110,200
| Closed | -$5.35M |
|
97
10x Genomics
TXG
$6.61B
| – | – |
-70,000
| Closed | -$2.55M |
|
|
VTYX
98
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-69,000
| Closed | -$2.26M |
|
99
Xenon Pharmaceuticals
XENE
$6.12B
| – | – |
-38,000
| Closed | -$1.5M |
|
|
CUTR
100
DELISTED
Cutera, Inc.
CUTR
| – | – |
-20,000
| Closed | -$884K |
|
Similar funds
TW
M
SG
FFA
GWM
Q
SIM
QT
Soleus Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Soleus Capital Management held 104 positions worth $966M, up 39% from $697M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Soleus Capital Management deployed $319M of net new capital in Q1 2023, opening 32 new positions and adding to 25 existing holdings. Its largest new stake was Smith & Nephew: 970,200 shares worth $27.1M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 97% a quarter earlier, followed by Consumer Staples.
On the sell side, the largest reduction was Vericel Corp, an estimated $16.9M trimmed.
- Soleus Capital Management's largest Q1 2023 buy was Smith & Nephew: 970,200 shares worth $27.1M.
- Soleus Capital Management added most to CVS Health in Q1 2023, an estimated $12.5M increase.
- Soleus Capital Management's biggest Q1 2023 reduction was Vericel Corp, cutting an estimated $16.9M.
- Soleus Capital Management fully exited CVRx in Q1 2023, selling an estimated $18.6M.
- Soleus Capital Management's ten largest holdings make up 50% of its $966M portfolio in Q1 2023.
- Soleus Capital Management opened 32 new positions and closed 27 in Q1 2023.
- Soleus Capital Management's portfolio value rose 39% quarter-over-quarter to $966M.
Based on Soleus Capital Management's 13F filing for Q1 2023, filed 15 May 2023.